Étienne Dardenne

Diamond Materials (United States) — United States

Medicine · Health Sciences

12h-index2.0kcitations67works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(28), Estrogen and related hormone effects(20), Radiopharmaceutical Chemistry and Applications(10), RNA Research and Splicing(7), Ubiquitin and proteasome pathways(6)

Publications67 total

1264P Real-world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Annals of Oncology·2024Open Access
Abstract 1229: BDTX-1535: A MasterKey EGFR inhibitor targeting classical and non-classical oncogenic driver mutations and the C797S acquired resistance mutation to address the evolving molecular landscape of EGFR mutant NSCLC
Cancer Research·2024· 5 cited
FIGURE 5 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
FIGURE 3 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
FIGURE 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
FIGURE 4 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Data Legends from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Data from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Table 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Figure 2 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
FIGURE 5 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
FIGURE 2 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Data Legends from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Data from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Figure 2 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Figure 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
FIGURE 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Figure 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
FIGURE 2 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Table 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

David S. Rickman(26), Himisha Beltran(25), Loredana Puca(25), Olivier Elemento(22), Mark A. Rubin(22), Lise Gratadou(19), Martin Dutertre(19), Didier Auboeuf(19), Kaitlyn Gayvert(18), Brian D. Robinson(18), Sophie Germann(18), Joanna Cyrta(17), Samaan Samaan(16), Verena Sailer(16), Aram Vosoughi(16), Nicholas J. Brady(16), Keltouma Driouch(15), Rosette Lidereau(15), Lucie Van Emmenis(15), Sheng‐Yu Ku(15)